Thursday’s Post-Mortem

Learn more about this firm

We want to ensure our investors know that we are standing side-by-side with them, as the stock market can do fairly illogical things from time to time. We’d like to discuss our three worst-performing securities in the US portfolio to help our investors understand why we are sitting on our hands and allowing our discipline to proceed. We are pounding the table at the opportunity within our grasp and wish to assure investors that we like what these circumstances are giving us. We believe they will guide us toward the successful outcomes that we have seen time and time again.

Merck (MRK)

Merck is one of the dominant pharmaceutical companies in the world, with a large expertise in oncology. The capital structure has about $25 billion of debt, net of cash, with a market cap of $218 billion as of today. Merck profits are still growing as they go from producing $18 billion in 2024 to likely north of $20 billion this year and the years moving forward. How can Merck underperform as much as it has in the last 12 months? The answer is not in how the business is operating. It’s in how investors choose to value it. Merck, beyond oncology, has an animal business that is plausibly worth $60 billion in a spin-off or third-party purchase. This is almost 30% of the current market capitalization of the business.

The company is currently trading at a price-to-cash flow multiple of 10.23 times. As the bear market of 2022 started roiling investors, stock market participants paid an average of about 17x cash flow for this business. That happened after the bear market reminded them why a consistent, staple business like Merck benefits them in hard times. This has been a stock that historically played a lower beta, defensive role in bad markets. Investors seem to have forgotten, as they did in 2021, at the current price/multiples on this company. We have not forgotten and can see how attractive this business is in the current environment.

APA Corp. (APA)

APA is an oil and gas company that is focused in the Permian, Egypt and has a prospective opportunity in Suriname and Alaska. Their capital structure is one of the most attractive in the oil business as they pay about 5.63% on their debt with an average duration of 10.35 years. If you look at the maturity schedule below, they have nothing more than $1 billion due over the next five years. We are pointing this out to our investors to show that the next five years of potential outcomes are not dependent on the capital structure. APA currently produces over $1 billion of free cash flow per year, despite the weakness in oil at the current spot price of around $66-$67.

SMEAD graph

Learn more about this firm